HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors

Frontiers in Cellular and Infection Microbiology

Cellular and Infection Microbiology

Juanjuan Fu¹  Li Li¹  Shifei Wen¹  Xiucheng Pan¹  Guangde Yang¹  Xia Wang¹  Jiaming Shen¹  Ningning Wang¹ 

[1] Department of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;

关键词: HBV-related HCC;    TACE;    TKIs;    ICIS;    HBV reactivation;   

DOI  :  10.3389/fcimb.2023.1179689

 received in 2023-03-04, accepted in 2023-04-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveThis study aimed to access hepatitis B virus (HBV) reactivation and its effect on survival in HBV-related hepatocarcinoma (HCC) patients who underwent transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs).MethodsIn this single-center retrospective study, we enrolled 119 HBV-related unresectable advanced HCC patients receiving TACE combined with TKIs plus ICIs. Risk factors for HBV reactivation were analyzed by logistic regression. Kaplan-Meier method was applied to draw the survival curve, and log-rank test was used to compare survival between patients with and without HBV reactivation.ResultsA total of 12 patients (10.1%) encountered HBV reactivation in our study, of which only 4 patients received antiviral prophylaxis. The incidence of HBV reactivation was 1.8% (1/57) in patients with detectable baseline HBV DNA and 4.2% (4/95) in patients with antiviral prophylaxis respectively. Lack of prophylactic antiviral treatment (OR=0.047, 95%CI 0.008-0.273, P=0.001) and undetectable HBV DNA (OR=0.073, 95%CI 0.007-0.727, P=0.026) were independent risk factors for HBV reactivation. The median survival time (MST) for all patients was 22.4 months. No survival difference was observed in patients with or without HBV reactivation. (MST: undefined vs 22.4 months, log-rank test: P=0.614).ConclusionHBV reactivation could occur in HBV-related HCC patients who treated with TACE in combination with TKIs plus ICIs. Before and during the combination treatment, it is necessary to routinely monitor HBV DNA and to take effective prophylactic antiviral therapy.

【 授权许可】

Unknown   
Copyright © 2023 Shen, Wang, Wang, Wen, Yang, Li, Fu and Pan